Takeda Oncology
Richard Gregory has extensive experience in the field of oncology and biochemistry, currently serving as the Director and Global Translational Lead at Takeda Oncology. Previously, Richard held roles as Associate Director and Senior Principal Scientist at Sanofi, and also served as Senior Principal Scientist and Laboratory Head at Harvard Medical School. Richard's academic journey includes time as a Postdoctoral Fellow at both the Dana-Farber Cancer Institute and Penn State University, where Richard completed a Ph.D. in Biochemistry after earning a B.S. in Biology from the same institution.
This person is not in any teams
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.